• Contact/
  • Home/

  • About
  • Team
  • Portfolio
  • Exit History
  • News

  • About
  • Team
  • Portfolio
  • Exit History
  • News

  • Advent Life Sciences
  • Advent Life Sciences

Page 1 of 25

 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10Next >End >>
04.08.2022F2G Announces $70 Million Financing to Advance Development and Commercialization of New Antifungal Agent Olorofim

Press Release

04.08.2022GILEAD SCIENCES TO ACQUIRE MIROBIO

Press Release

01.07.2022Aura Biosciences Receives FDA Fast Track Designation for Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer

Press Release

28.06.2022Wondr Medical raise £12 million in Seed round to accelerate global collaboration across the medical community

Press Release

14.06.2022PROXIMIE RAISES $80 MILLION IN SERIES C FUNDING TO ACCELERATE PRODUCT EXPANSION OF FULL-SERVICE CONNECTED SURGICAL PLATFORM

Press Release

26.05.2022Aura Biosciences Announces Publication of Preclinical Data of the Combination of VDCs with Immune Checkpoint Inhibitors at the 2022 ASCO Annual Meeting

Press Release

25.05.2022Advent Life Sciences Announces Growth of Investment Team with Three Senior Appointments

Press Release

16.05.2022Shionogi & Co., Ltd. and F2G Ltd., Enter Strategic Collaboration to Develop and Commercialize the New Antifungal Agent Olorofim in Europe and Asia

Press Release

11.05.2022Artax Biopharma Closes Financing to Advance Clinical Stage First-in- Class Oral Immunomodulator to Treat T Cell-Mediated Diseases

Press Release

04.05.2022Amphista Therapeutics Enters Strategic Collaboration with Merck for Discovery and Development of Targeted Protein Degradation Therapeutics

Press Release



  • Privacy Policy
  • Legal and Regulatory Matters

©2022 Advent Life Sciences